rilmenidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, clonidine derivatives 2381 54187-04-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rilmenidine
  • oxaminozoline
  • rilmenidene
  • rilmenidine phosphate
  • rilmenidine dihydrogen phosphate
Oxazole derivative that acts as an agonist for ALPHA-2 ADRENERGIC RECEPTORS and IMIDAZOLINE RECEPTORS. It is used in the treatment of HYPERTENSION.
  • Molecular weight: 180.25
  • Formula: C10H16N2O
  • CLOGP: 1.42
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 33.62
  • ALOGS: -2.13
  • ROTB: 3

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 4.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.90 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 309.89 32.89 197 3712 240566 56047592
Lactic acidosis 241.24 32.89 91 3818 35255 56252903
Hyperkalaemia 134.22 32.89 67 3842 50798 56237360
Allergic reaction to excipient 101.57 32.89 18 3891 321 56287837
Hyponatraemia 91.01 32.89 67 3842 102072 56186086
Mixed liver injury 79.24 32.89 23 3886 3921 56284237
Rhabdomyolysis 74.41 32.89 42 3867 40616 56247542
Isosthenuria 69.12 32.89 11 3898 98 56288060
Pyelitis 63.31 32.89 11 3898 174 56287984
Bladder hypertrophy 61.01 32.89 11 3898 217 56287941
Electrocardiogram PR shortened 59.87 32.89 11 3898 242 56287916
Angioedema 57.96 32.89 36 3873 41417 56246741
Toxic skin eruption 51.37 32.89 22 3887 11717 56276441
Multiple organ dysfunction syndrome 50.05 32.89 36 3873 52734 56235424
Eye oedema 45.45 32.89 12 3897 1443 56286715
Creatinine renal clearance increased 44.73 32.89 10 3899 598 56287560
Fall 43.67 32.89 84 3825 357426 55930732
Carbohydrate antigen 15-3 increased 42.18 32.89 11 3898 1260 56286898
Prevertebral soft tissue swelling of cervical space 39.78 32.89 6 3903 36 56288122
Carcinoembryonic antigen increased 39.59 32.89 11 3898 1601 56286557
Peripheral artery haematoma 39.37 32.89 6 3903 39 56288119
Drug reaction with eosinophilia and systemic symptoms 39.04 32.89 25 3884 30279 56257879
Primary hyperaldosteronism 37.85 32.89 6 3903 52 56288106
Myoclonus 37.01 32.89 19 3890 15184 56272974
Intestinal transit time abnormal 36.31 32.89 6 3903 69 56288089
Bradycardia 36.19 32.89 33 3876 67471 56220687
Overdose 35.26 32.89 40 3869 105790 56182368
Psychomotor retardation 34.50 32.89 12 3897 3657 56284501
Hypochloraemia 34.45 32.89 10 3899 1702 56286456
Cholestasis 34.17 32.89 22 3887 26891 56261267
Renin decreased 34.12 32.89 6 3903 102 56288056

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 151.84 27.72 138 2126 279576 31415504
Cerebral haematoma 63.49 27.72 20 2244 4375 31690705
Lactic acidosis 63.09 27.72 35 2229 31902 31663178
Necrotising oesophagitis 51.50 27.72 11 2253 517 31694563
Hyperkalaemia 51.42 27.72 40 2224 64311 31630769
Hypovolaemic shock 48.47 27.72 18 2246 6444 31688636
Hemiplegia 33.74 27.72 14 2250 6708 31688372
Tubulointerstitial nephritis 30.40 27.72 18 2246 18478 31676602
Product name confusion 29.41 27.72 5 2259 67 31695013
Pemphigoid 27.81 27.72 13 2251 8258 31686822

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 406.30 25.96 333 5924 474291 70447896
Lactic acidosis 267.07 25.96 125 6132 64899 70857288
Hyperkalaemia 163.37 25.96 107 6150 106484 70815703
Allergic reaction to excipient 98.75 25.96 18 6239 294 70921893
Hyponatraemia 83.91 25.96 86 6171 160001 70762186
Isosthenuria 66.19 25.96 11 6246 101 70922086
Mixed liver injury 59.69 25.96 22 6235 6227 70915960
Cerebral haematoma 56.14 25.96 22 6235 7356 70914831
Electrocardiogram PR shortened 55.85 25.96 11 6246 276 70921911
Pyelitis 55.62 25.96 11 6246 282 70921905
Angioedema 54.66 25.96 46 6211 66564 70855623
Hypovolaemic shock 47.98 25.96 22 6235 10815 70911372
Bladder hypertrophy 47.86 25.96 11 6246 584 70921603
Necrotising oesophagitis 45.88 25.96 11 6246 702 70921485
Pemphigoid 45.50 25.96 23 6234 13999 70908188
Rhabdomyolysis 42.23 25.96 47 6210 95713 70826474
Carbohydrate antigen 15-3 increased 41.57 25.96 11 6246 1047 70921140
Toxic skin eruption 40.27 25.96 24 6233 20138 70902049
Ischaemic stroke 40.07 25.96 28 6229 30792 70891395
Fall 40.06 25.96 107 6150 443989 70478198
Eye oedema 39.48 25.96 12 6245 1880 70920307
Creatinine renal clearance increased 38.78 25.96 10 6247 860 70921327
Prevertebral soft tissue swelling of cervical space 38.35 25.96 6 6251 36 70922151
Overdose 37.03 25.96 59 6198 169686 70752501
Hypokalaemia 36.34 25.96 51 6206 131137 70791050
Multiple organ dysfunction syndrome 35.89 25.96 46 6211 108469 70813718
Intestinal transit time abnormal 34.87 25.96 6 6251 69 70922118
Carcinoembryonic antigen increased 34.49 25.96 11 6246 2019 70920168
Hemiplegia 34.33 25.96 19 6238 13876 70908311
Blood aldosterone increased 34.18 25.96 7 6250 215 70921972
Peripheral artery haematoma 33.33 25.96 6 6251 91 70922096
Renin decreased 32.00 25.96 6 6251 115 70922072
Primary hyperaldosteronism 31.26 25.96 6 6251 131 70922056
Renal failure 31.10 25.96 58 6199 189012 70733175
Breast cancer recurrent 31.04 25.96 11 6246 2782 70919405
Drug reaction with eosinophilia and systemic symptoms 30.01 25.96 31 6226 57982 70864205
Hypochloraemia 29.84 25.96 10 6247 2141 70920046
Myoclonus 29.80 25.96 22 6235 26333 70895854
Intestinal haemorrhage 29.12 25.96 13 6244 6007 70916180
Hypertension 28.33 25.96 73 6184 295960 70626227
Psychomotor retardation 26.79 25.96 12 6245 5586 70916601
Confusional state 26.05 25.96 69 6188 284329 70637858

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02AC06 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Imidazoline receptor agonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013565 Sympatholytics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR Ki 7.44 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 5.05 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 7.37 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 7.90 CHEMBL
Nischarin Membrane receptor Ki 7.23 CHEMBL
Nischarin Unclassified Ki 7.95 CHEMBL

External reference:

IDSource
D08482 KEGG_DRUG
C0140591 UMLSCUI
CHEBI:8862 CHEBI
CHEMBL289480 ChEMBL_ID
DB11738 DRUGBANK_ID
D000077769 MESH_DESCRIPTOR_UI
68712 PUBCHEM_CID
5846 INN_ID
85409-38-7 SECONDARY_CAS_RN
P67IM25ID8 UNII
236379 RXNORM
005772 NDDF
005773 NDDF
765332006 SNOMEDCT_US
765333001 SNOMEDCT_US

Pharmaceutical products:

None